Opus Genetics (NASDAQ:IRD) reported quarterly losses of $(0.24) per share which beat the analyst consensus estimate of $(0.25) by 4 percent. This is a 17.24 percent increase over losses of $(0.29) per share from the same period last year. The company reported quarterly sales of $4.37 million which beat the analyst consensus estimate of $3.10 million by 41.03 percent. This is a 155.41 percent increase over sales of $1.71 million the same period last year.